Nervgen Pharma (NGEN) Common Equity (2024 - 2026)

Nervgen Pharma (NGEN) posted quarterly Common Equity of $4.0 million for Q1 2026, up 62.08% quarter-over-quarter from $2.5 million in Q4 2025.

Nervgen Pharma (NGEN) Common Equity (2024 - 2026) Analysis & Trends

Nervgen Pharma (NGEN) has reported Common Equity for 3 consecutive years, with $4.0 million the latest figure, recorded in Q1 2026.

In Q1 2026, Common Equity changed N/A year-over-year to $4.0 million; the TTM figure through Mar 2026 stood at $4.0 million (changed N/A YoY), while the FY2025 annual figure was $2.5 million, up 35.18% from the prior year.
Common Equity improved to $4.0 million in Q1 2026 per NGEN's latest filing, from $2.5 million in the prior quarter.
Across five years, Common Equity topped out at $4.0 million in Q1 2026 and bottomed at $1.8 million in Q4 2024.
Historically, Common Equity has averaged $2.8 million across 3 years, with a median of $2.5 million in 2025.
On a YoY basis, Common Equity climbed as much as 35.18% in 2025 and fell as far as 35.18% in 2025.
Nervgen Pharma's Common Equity stood at $1.8 million in 2024, then jumped by 35.18% to $2.5 million in 2025, then surged by 62.08% to $4.0 million in 2026.
Business Quant data shows NGEN's Common Equity at $4.0 million in Q1 2026, $2.5 million in Q4 2025, and $1.8 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Common Equity (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	20.25 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	31.71 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	6.76 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	5.17 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.35 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	757.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	9.79 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	22.38 Bn
10	Nervgen Pharma	161.78 Mn	161.78 Mn	-	12.49 Mn

Download Data